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Over the past two decades, a number of studies have failed to provide direct evidence of speciﬁc
microbial chronic infection in primary biliary cirrhosis (PBC). However, a recent report suggests that
there is a speciﬁc association of Chlamydia pneumoniae in patients with PBC and that C. pneumoniae
or similar antigens might play a role in the pathogenesis of disease. To determine if Chlamydia
infection is associated with PBC, we applied a combination of immunological and molecular
approaches to investigate (a) the serological reactivity against two common Chlamydia human
pathogens, C. pneumoniae and C. trachomatis, by immunoblotting, (b) the presence of Chlamydia in
liver samples of patients with PBC and controls by PCR ampliﬁcation of Chlamydia speciﬁc 16S rRNA
and (c) the presence of Chlamydia proteins in liver samples of patients with PBC and controls by
immunohistochemical staining. By immunoblotting, C. trachomatis and C. pneumoniae speciﬁc
serological antibodies were found in 52/57 (91.2%) AMA positive PBC, 7/33 (21/2%) of AMA
negative PBC, 1/25 (4%) PSC, 0/15 (0%) Sjorgen’s syndrome and 0/20 (0%) systemic lupus
erythematosus patients and 0/20 (0%) healthy volunteers at 1:200 sera dilution. PBC sera reacted to
Chlamydia and E. coli lysates in western blots up to a maximum of 10
24 dilution. However, PCR
ampliﬁcation of the Chlamydia speciﬁc 16S rRNA gene was negative in 25/25 PBC livers but positive
in 1/4 PSC liver, 3/6 in other liver disease controls and 1/4 normal liver samples. While two
commercially available speciﬁc monoclonal antibodies stained positive controls (Chlamydia infected
HEp-2 cells) they failed to detect Chlamydia antigens in PBC livers. The detection of Chlamydia
speciﬁc antibodies but not Chlamydia rRNA gene and Chlamydia antigens in PBC suggests that
Chlamydia infection is not involved in PBC.
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INTRODUCTION
The breaking of tolerance by molecular mimicry of self-
antigens by microbial proteins is an attractive hypothesis
in the etiology of primary biliary cirrhosis (PBC)
(Bjorkland and Totterman, 1994; Baum, 1995; Sutton
and Neuberger, 2002; Datta, 2003; Hayakawa et al., 2003;
Plotz, 2003). PBC is serologically characterized by high
titer anti-mitochondrial antibodies (AMA) in 95% of
patients (Gershwin et al., 2000). AMA are directed against
E2 subunits of the 2- oxo-acid dehydrogenase complexes
(2-OADC), and also against subunits E1 alpha, E1 beta
and E3 binding protein of the pyruvate dehydrogenase
complex (Leung et al., 1997; Dubel et al., 1999). AMA of
PBCpatientsalsoreactwithbacterial E2s(Gershwinetal.,
2000). Reactivities are primarily peptide-speciﬁc but
cross-reactivity between mitochondrial and microbial E2
antigens of respective complexes have been reported
(Fussey et al., 1990). The AMA immunodominant
epitopes include the conserved sequence ﬂanking the
site of lipoyl attachment site of the 2-OADC.
It has been postulated that the initial stimulus for
antibody production is chronic urinary tract infection
(Baum, 1995). A number of studies have demonstrated
signiﬁcant bacteriuria in patients with PBC, with E. coli
as the most common urinary isolate (Burroughs et al.,
1984; Rabinovitz et al., 1992; Butler et al., 1993;
O’Donohue et al., 1997). For example, E. coli rough
forms were found in the urine of patients with
signiﬁcant bacteriuria including 39% in patients with
PBC, 5.3% in patients with chronic liver disease and
41% in patients from the recurrent urinary tract
infection group. Cross-reactivity between AMA
and corresponding antigenic bands of E.coli has
been demonstrated in sera from patients with PBC
suggesting that AMA arise in “normal” women
with recurrent bacteriuria and in females with PBC
(Butler et al., 1993).
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responsible for breaking the immune tolerance with
mitochondrial proteins. For example, Xu et al. reported
the evidence of human betaretrovirus infection in lymph
nodes of patients with PBC by RT-PCR and immuno-
histochemistry (Xu et al., 2003). Screening of random
peptide libraries with a PDC-E2 speciﬁc monoclonal
antibody yielded eight different peptide sequences with
little consensus (Cha et al., 1996). Tanaka et al. concluded
that no consensus 16S rRNA microbial sequence could be
found in PBC liver specimens by PCR ampliﬁcation from
liver tissue specimens from patients with PBC and non-
PBC controls (Tanaka et al., 1999). Altogether, these
approaches, although rigorous could not identify any
infectious agent speciﬁc associated with PBC.
Recently, it has been suggested Chlamydia pneumoniae
or similar antigens play an important role in the
pathogenesis of PBC (Abdulkarim et al.,2 0 0 2 a , b ) .
Brieﬂy, C.pneunomiae antigens were detected in explant
liver specimens from 25/25 patients with PBC (2 of whom
were antimitochondrial antibody-negative) by immuno-
histochemistry. C. pneumoniae antigens were detected in
periportal and lobular hepatocytes of PBC livers, whereas
only 9/105 (8.5%) of patients in other categories (primary
sclerosing cholangitis (PSC), alcoholic liver disease and
chronic hepatitis C combined) were positive (p , 0:01;
Fisher’s exact T test). To verify that Chlamydia infection
is associated with PBC, we have probed the antibody
reactivities of PBC and control sera samples against
two common Chlamydia species; C. pneumoniae and
C. trachomatis, pursued PCR based molecular detection in
liver samples of control and PBC patients of Chlamydia
speciﬁc 16S rRNA gene and sought to demonstrate the
presence of the two Chlamydia types by immuno-




A total of 170 sera samples were used in this study.
These include sera from patients with PBC ðn ¼ 90Þ; PSC
ðn ¼ 25Þ; systemic lupus erythematosus ðn ¼ 20Þ;
Sjogren’s syndrome ðn ¼ 15Þ and healthy volunteers
ðn ¼ 20Þ: All patients were diagnosed according to
established criteria (Kaplan, 1996; Venables, 1998; Lee
and Kaplan, 1999; Lee and Kaplan, 2002). In addition the
sera from patients with PBC have been tested for the
presence of AMA as described (Tanaka et al., 2002),
which revealed 57 AMA positive and 33 AMA negative
sera. Anti-lipoic acid antibody was generated as described
(Humphries and Szweda, 1998). Anti-Chlamydia anti-
bodies were obtained from Virostat (Portland, ME).
Monoclonal antibodies against 2-OADC-E2 were genera-
ted by immunization of Balb c mice with a recombinant
triple hybrid containing the AMA epitopes of PDC-E2,
BCOADC-E2 and OGDC-E2 (Migliaccio et al., 1998).
Tissue Samples
Explant liver specimens from 25 patients with PBC and 36
controls were studied. The PBC livers included 5 patients
classiﬁed as stage I and II and 20 patients classiﬁed as
stage III and IV. Controls included livers from
patients with PSC ðn ¼ 10Þ; other liver diseases including
hepatitis ðn ¼ 6Þ; cryptic cirrhosis ðn ¼ 8Þ and alcoholic
liver disease ðn ¼ 8Þ as well as normal liver samples
ðn ¼ 4Þ.
Preparation of Recombinant Proteins
Recombinant peptides of mammalian PDC-E2,
BCOADC-E2, OGDC-E2 were puriﬁed from the corres-
ponding expression clone in pGEX (Moteki et al., 1996).
Brieﬂy, the E coli clone was grown in LB containing
50mg/ml of ampicillin and induced with 1mM isopropyl
beta-D-thiogalactoside (Alexus, San Diego, CA) for 6h.
Cells were harvested and recombinant proteins were
puriﬁed using glutathione agarose (Sigma) as described
(Moteki et al., 1996). An irrelevant expression protein of
the shrimp tropomyosin in pGEX (Leung et al., 1994) was
puriﬁed similarly.
Serological Immunoreactivity against Chlamydia by
Immunoblotting
Chlamydia trachomatis elementary bodies were obtained
from Advanced Biotechnologies (Columbia, Maryland).
C. pneumoniae was prepared from HEp-2 cells culture as
described (Tjhie et al., 1997). A measured quantity of
100mgo fChlamydia lysate was resolved on 10% SDS-
polyacrylamide gel electrophoresis (SDA-PAGE) and
transferred to nitrocellulose membrane. The membrane
was then cut into 3mm strips, blocked with 3% non-fatdry
milk in phosphate buffered saline (PBS) for 1h and then
incubated with human sera (1:200 dilution) for 1h.
Membranes are then washed with PBS containing 0.05%
tween 20 for 4 times, 10min each before incubating
with horseradish peroxidase conjugated anti-human Ig
(Zymed, South San Francisco, CA for 1h at room
temperature. Membranes were then washed with PBS
containing 0.05% tween 20. Antibody binding was
visualized by incubating with a 0.05% solution of 3, 30
diamino-benzidine (Sigma) and 0.01% hydrogen per-
oxide. To determine the identity of the Chlamydia
immunoreactive bands, PBC sera (1:200 dilutions) were
preincuabted with 100mg of recombinant proteins of
PDC-E2, BCOADC-E2 and OGDC-E2 and the
irrelevant antigen noted above at 48C for overnight prior
to probing against Chlamydia by immunoblotting.
In addition, 100mgo fChlamydia lysate and the
same amount of E.coli lysate were resolved by SDS-
PAGE, and transferred onto nitrocellulose membrane.
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3–10
6 of sera dilutions were
analyzed by immunoblotting against equal concentrations
of Chlamydia and E. coli lysate followed by chemilumi-
nescent detection (Pierce, Rockford, IL).
PCR Ampliﬁcation of Chlamydia 16S rRNA Gene
Total DNA was isolated from explant liver samples using
the QIAmp DNA mini-kit (Qiagen, Valencia, CA)
according to manufacturer’s instruction. Touch down
polymerase chain reaction (PCR) was conducted to
amplify the 16S rRNA gene of C. pneumoniae from liver
DNA samples using speciﬁc primers (CpnA): 50-TGAC-
AACTGTAGAAATACAGC-30 and (CpnB): 50-CGCCT-
CTCTCCTATAAAT-30 as described (Gaydos et al., 1992;
Gaydos et al., 1994a,b; Boman et al., 1999). Similarly, the
C.trachomatis 16S rRNA gene was ampliﬁed using
speciﬁc primers (CtnA): 50-TGACCGCGGCAGAAATG-
TCGT-30 and (CtnB) 50-CGCCTCTCTCCCTTGCGG-30
as described (Gaydos et al., 1992; Gaydos et al., 1994a,b;
Boman et al., 1999). C.pneumoniae and C.trachomatis
DNA were included as controls. Brieﬂy, the react-
ion mixture contained liver DNA samples, 0.5mM
primers, 0.2mM dNTPs, 1 £ PCR buffer and 1unit of
Taq polymerase. Samples were subjected to 6 cycles of
denaturation (948C, 1min), annealing (60–548C, 18C
step down each cycle, 1min) and extension (728C, 1min),
followed by 30 cycles of denaturation (948C, 1min),
annealing (558C, 1min) and extension (728C,
1min). Negative (DNAse, RNAse free water and
DNA extracted from E.coli) and positive controls
(DNA extracted from C.pneumoniae and C.trachomatis)
were included. PCR products were resolvedby agarose gel
electrophoresis and visualized by ethidium bromide
staining (0.5mg/ml). Positive and negative controls are
included throughout (Boman et al., 1999).
Immunohistochemical Staining
Immunohistochemical staining with monoclonal anti-
bodies against C. pneumoniae were performed on liver
sections from patients with PBC ðn ¼ 10Þ and other
disease controls (six PSC, one alcoholic liver cirrhosis,
ﬁve cryptic cirrhosis and six Non-A, Non-B hepatic
cirrhosis). Brieﬂy, parafﬁn sections were incubated at
658C for overnight and deparafﬁnized in four changes of
xylene. The slides were then washed in two 100% alcohol
and two 95% alcohol rinses and then ﬁnally rinsed in tap
water. The slides were washed in phosphate buffered
saline (PBS, pH 7.4) and incubated with blocking solution
(1.5% of normal horse serum in PBS). Following
blocking, slides were incubated with 1:20 diluted
monoclonal antibody against C.pneumoniae (Virostat,
Portland, ME) for 1h in a humidiﬁed chamber and
thereafter washed three times in PBS. After that, the slides
were incubated with biotin labelled anti-mouse-IgG
for 30min and washed three times in PBS before
incubating with avidin and biotinylated HRP complex
(Vector Laboratories, Burlingame, CA) solution. Reactiv-
ity was visualized by the addition of alkaline phosphatase
substrate. (The slides were mounted with crystal mounting
medium and analyzed by ﬂuorescent microscopy using
the Olympus Provis Microscope (Olympus America,
Melille, NY).
RESULTS
Serological Immunoreactivity against Chlamydia
By immunoblotting, Chlamydia speciﬁc serological
antibodies were found in 52/57 (91.2%) AMA positive
PBC and 7/33 (21.2%) of AMA negative PBC sera. Out of
the 90 PBC sera, 59(65.6%) reacted with C.trachomatis
and 51(56.7%) reacted with C.pneumoniae. 1/25 (4%)
of PSC sera reacted to both C. trachomatis and
C.pneumoniae, 0/15 (0%) of Sjorgen syndrome and 0/20
(0%) of systemic lupus erythematosus patients and 0/20
(0%) of healthy subjects reacted to either of the
Chlamydia species (Table I). Moreover, the identities of
the major Chlamydia reactive proteins were determined
as the E2 subunits of 2-oxo-acid dehydrogenase
complex by the antigen inhibition studies and
conﬁrmed by their speciﬁc reactivities to monoclonal
antibodies to mammalian 2-OADCC- E2 (Fig.1).
Irrelevant recombinant protein of the shrimp tropomyosin
did not inhibit.
TABLE I Serological reactivity to Chlamydia by immunoblotting
Chlamydia species Group (No. of samples) No. of positive samples/total (%)
Chlamydia trachomatis Primary biliary cirrhosis ðn ¼ 90Þ 59/90 (65.6%)
Primary sclerosing cholangitiss ðn ¼ 25Þ 1/25 (4%)
Sjogren’s syndrome ðn ¼ 15Þ 0/15 (0%)
Systemic lupus erythematosus ðn ¼ 20Þ 0/20 (0%)
Normal ðn ¼ 20Þ 0/20 (0%)
Chlamydia pneumoniae Primary biliary cirrhosis ðn ¼ 90Þ 51/90 (56.7%)
Primary sclerosing cholangitis ðn ¼ 25Þ 1/25 (4%)
Sjogren’s syndrome ðn ¼ 15Þ 0/15 (0%)
Systemic lupus erythematosus ðn ¼ 20Þ 0/20 (0%)
Normal ðn ¼ 20Þ 0/20 (0%)
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16S rRNA Gene
PCR ampliﬁcation of C. trachomatis and C. pneumoniae
speciﬁc16S rRNA gene showed that neither Chlamydia
16S rRNA gene was present in livers from patients with
PBC, but was present in low percentage of the other
controls (Table II).
Immunohistochemical Detection of Chlamydia in
Liver Samples
C. pneumoniae were not detected on the bile ducts and
hepatocytes of the liver sections from 10 PBC patients as
well as 18 livers sections from other disease controls.
Titer of PBC Patient Sera against Chlamydia and
E. coli
PBC sera reacted to both Chlamydia and E. coli at 10
23
and 10




The underlying mechanism(s) in the breaking of immune
tolerance is one of the most important issues in the
etiopathology of autoimmune diseases. One hypothesis is
based on molecular mimicry, i.e. mimicry by infectious
agents of host antigens may induce cross-reactive
autoimmune responses to epitopes within host proteins
which, in susceptible individuals, may tip the balance
towards mounting an immunological response and sub-
sequently lead to autoimmune disease (Davies, 1997).
In fact, a number of reports support this hypothesis (Zhao
etal.,1998;FournelandMuller,2002).Ithasbeensuggested
that infection can probably cause T cell activation in
multiple sclerosis (MS) susceptible individuals (Haﬂer,
1999)andseveralmicrobialagentsincludingC.pneumoniae
have been implicated as the intracellular pathogens causing
MS (Hunter and Haﬂer, 2000). On the other hand, a search
for molecular mimicry in PBC has been done using
monoclonal antibodies to PDC-E2 and random peptide
libraries (Cha et al., 1996; Leung et al., 1996) and found
mimeotope peptides that did not show any signiﬁcant
sequence homology to any known microbial peptides and
did not generate PBC in animals.
Based on the signiﬁcantsequence homology between the
AMA epitopes and the E.coli lipoyl enzymes, it
was hypothesized that the initial stimulus for AMA
production may result from chronic urinary tract infection
(Baum, 1995). Although AMA themselves are not
pathogenic,antigenspeciﬁcCD4þ Tcellscouldbeprimed,
recognizing the lipoyl domain epitope in association with
classIIHLAandinitiatetheautoimmunecascadeinpatients
with PBC. The association of urinary tract infections in
patients with PBC has been studied and the data are
inconclusive (Burroughs et al., 1984; Rabinovitz et al.,
1992;Butleretal.,1993;O’Donohueetal.,1997).Similarly,
data on association of PBC with other microbial agents
remain elusive (Tanaka et al., 1999; Heathcote, 2000;
Samonakis et al.,2 0 0 3 ) .W eh a v eu s e dat h r e ep r o n e
approachtodetermineifChlamydia infection is involved in
thepathogenesisofPBCthroughtheuseofacombinationof
immunological and molecular approaches.
Chlamydia are obligate intracellular eubacteria which
are phylogenetically distinct from other bacteria.
Two well-known Chlamydia human pathogens are
FIGURE 1 Immunoreactivity of Chlamydia pneumoniae lysate. Note
the reactivity with anti-lipoic acid antibody (lane 1), monoclonal
antibody to PDC-E2 (lane 2); to OGDC-E2 (lane 3); to BCOADC-E2
(lane 4); Sera (1:1000) from patients with PBC (lane 5); Sera from
patients with PBC after absorption with 3% non-fat dry milk in PBS
(lane 6) and the lost of reactivity to a 70KDa band when PBC serum is
ﬁrst absorbed with recombinant PDC-E2 (lane 7); lost of reactivity to a
45KDa band when PBC serum is ﬁrst absorbed with recombinant
OGDC-E2 (lane 8).
FIGURE2 LysatesofE.coli(A)and C.pneumoniae(B)were separated
by SDS-PAGE, transferred to nitrocellulose and probed with a
representative serum from a AMA positive patient with PBC at serial
dilutions of 10
23–10
26. Note the reactivity to both: E. coli lysate (A)
and C. pneumoniae lysate (B) at sera dilutions of 10
23 and 10
24 (lanes 1
and 2) but not at 10
25 and 10
26 sera dilution (lanes 3 and 4).
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P.S.C. LEUNG et al. 230C. pneumoniae and C. trachomatis. C. pneumoniae is a
widespread pathogen of humans causing pneumonia and
bronchitis and it accounts for approximately 10% of
pneumonia and 5% of bronchitis cases in the United
States. In addition, there are reports associating
C. pneumoniae infection with atherosclerosis and
abdominal aortic aneurysm (Danesh et al., 1997; Juvonen
et al., 1997a; Juvonen et al., 1997b). C. trachomatis
infection causes trachoma, an ocular infection that leads to
blindness and sexually transmitted diseases (Tabbara,
2001; Gaynor et al., 2003; Jensen et al., 2003). Analysis of
the C. pneumoniae and C. trachomatis genome (Kalman
et al., 1999) showed that the two genomes have a low level
of DNA homology to the mammalian genome. However,
genes for central metabolic pathways, including aerobic
respiration are present and electron transport may be
supported by pyruvate. Thus, it is not surprising that lipoyl
containing proteins, which are necessary in mammalian
aerobic respiration, are detectable in Chlamydia when
anti-lipoic acid antibody was used as a probe (Fig. 1).
Furthermore, the Chlamydia lipoic acid containing
proteins are recognized by AMA and the Ig reactivity
can be inhibited by absorption with recombinant E2
proteins of the 2-OADC pathway (Fig. 1), suggesting that
AMA in PBC are binding to the lipoyl domains of the
Chlamydia homologue of the mammalian respiratory
enzymes. 65.6% of the PBC sera sample tested reacted
positively to Chlamydia, which is similar to the
prevalence of antibodies to C. pneumoniae (40–60%)
in the general population (Cook and Honeybourne, 1995;
Niki and Kishimoto, 1996). It is interesting to note that a
surprisingly low percentage of control sera reacted
positively to either C. pneumoniae or C. trachomatis.O n
the other hand, 70% of the PBC sera, were positive to
C. trachomatis. When the titer of PBC sera against
Chlamydia vs. against E. coli, PBC sera reacted to both
E. coli and Chlamydia at sera dilutions up to 10
4 as
detected by chemiluminescence. This modest titer
suggests that the serological antibody reactivity to
Chlamydia is at best comparable to other common
human microbes.
PCR is a highly sensitive and speciﬁc method for
detection and quantiﬁcation of speciﬁc nucleic acids and
its application to the detection of slow growing
microorganisms in autoimmune diseases has been recently
reviewed (Cuchacovich et al., 2003). C. pneumoniae and
C. trachomatis speciﬁc 16S rRNA was not detected in any
of the PBC liver samples but present in low percentages in
the other liver disease control and normal volunteers.
Due to the ubiquitous nature of Chlamydia, special
precautions were speciﬁcally used to avoid not only false
positive and but care was taken to avoid generating false
negative results in the detection of Chlamydia by PCR.
Thus, the absence of any Chlamydia speciﬁc 16S rRNA
gene in PBC livers seems unlikely to be due to
experimental or technical issues such as DNA quality,
primer speciﬁcities and reaction conditions. Of note, C.
pneumoniae has been reported to have a strong association
with patients with MS, but a recent report using a large
population of MS patients and controls was unable to
conﬁrm the increase presence of C. pneumoniae genome
in the spinal ﬂuid of MS patients (Boman et al., 2000;
Krametter et al., 2001). Furthermore, a surprisingly low
prevalence of C. trachomatis infection was reported in the
three studies using PCR (1.06, 0 and 1.48%, respectively)
giving an overall prevalence of 0.98% (Andreu Domingo
et al., 2002). Thus the detection of Chlamydia speciﬁc
antibodies but not Chlamydia rRNA gene and Chlamydia
antigens in PBC suggests that Chlamydia infection is not
involved in PBC.
Despite multiple and rigorous studies, the linkage
between microbial infections and autoimmune diseases
remains still elusive. The apparent lack of involvement of
Chlamydia infection in PBC as reported here suggests that
the molecular mimicry hypothesis in PBC may require
modiﬁcation. Recently, the hypothesis that PBC may
be due to an initial insult with an environmental agent,
possibly as a xenobiotic agent has been explored
(Sasaki et al., 2000; Long et al., 2001). Since optimal
reactivity of AMA requires the lipoyl domain as a
component of the autoantigen (Migliaccio et al., 2001), its
structural conﬁguration has been reasoned to be important
for the breakdown of self tolerance in PBC. Hence,
exposure of genetically susceptible individuals to a
xenobiotic agent, which mimics the lipoylated peptide of
PDC-E2, may be important in the etiology of PBC. In a
recent study, we synthesized the immunodominant 12
amino acid peptide epitope within the inner lipoyl domain
of PDC-E2 and replaced the lipoic acid moiety with a
battery of synthetic structures designed to mimic a
xenobiotically-modiﬁed lipoyl hapten, and quantiﬁed the
reactivities of these structures with sera from PBC
patients. Particularly noteworthy was our ﬁnding that
AMA from all patients with PBC, but not controls, reacted
against several of the organic modiﬁed mimetopes as well
as, or signiﬁcantly better than, to the native lipoyl domain
(Long et al., 2001). This is further supported by the recent
data that rabbits immunized by one of such xenobiotic
agents, 6-bromohexanote induced the production of
AMA (Leung et al., 2003). Most recently, a speciﬁc
association of a unique xenobiotic metabolizing bacteria
Novosphingobium aromaticivroans (Takeuchi et al.,
2001; Pinyakong et al., 2003) and PBC has been reported
(Selmi et al., 2003). N. aromaticivorans is ubiquitous in
the environment (Takeuchi et al., 2001; Fujii et al., 2002;
Tiirola et al., 2002; Fujii et al., 2003) and has the highest
homology in the lipoyl domains between two of its
lipoylated proteins and the human PDC-E2 in the known
microbial world. Moreover, 100% (77/77) of anti-PDC-E2
positive and 12% (2/17) of AMA negative sera from
patients with PBC recognize these two lipoyl containing
proteins, while no such reactivity was detected in 200
control sera. Antibody titers to these N. aromaticivorans
lipoyl-containing proteins was detectable even at dilutions
of 1:1,000,000 and were up to 1000-fold stronger than
the titers for E. coli lipoylated proteins. In addition to
INFECTION AND PBC COINFECTION 231the reactivity towards these two lipoylated proteins, sera
from patients with PBC also recognize other non-
lipoylated N. aromaticivorans proteins. Moreover, PCR
ampliﬁcation of the N. aromaticivorans 16S rRNA gene
from fecal samples showed that N. aromaticivorans is
present in approximately 25% of PBC patients and
controls.Altogether,thesedatathesuggeststhatxenobiotic
modiﬁcation of lipoyl moiety of the N. aromaticivorans
PDC-E2 homologues as a possible mechanism in the
etiology of PBC. The origin of autoimmunity is clearly
multifactorial and molecular mimicry of infectious agent
itself cannot fully account for the speciﬁcities and
spectrum of autoimmune diseases. The role of xeno-
biotics, in conjunction with presence of xenobiotic
metabolizing microorganisms and the hypothesis of
molecular mimicry in the induction of autoimmune
diseases (Pumford and Halmes, 1997) warrant further
investigation.
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